THE OCULAR TOLERABILITY OF A NEW OPHTHALMIC DRUG-DELIVERY SYSTEM (NODS)

被引:14
|
作者
DIESTELHORST, M
KRIEGLSTEIN, GK
机构
[1] University Eye Hospital of Cologne, Cologne 41, 5000
关键词
GLAUCOMA; OPHTHALMIC DRUG DELIVERY SYSTEMS; VISUAL ANALOG SCALES;
D O I
10.1007/BF00919405
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
In an open label, two period cross-over study we compared the ocular tolerability of NODS vs. Isopto-Naturale(R) eye drops. Thirty healthy volunteers were asked to rate the application system they were using for ocular discomfort, utilizing a visual analog scale in which 100 = no ocular discomfort and 0 = severe ocular discomfort. In addition each subject had to answer a questionaire and underwent a full ophthalmic control before, at day 7, at day 14 and at day 21 of the study. Each application form had to be applied to one eye only once a day for 7 days, followed by a washout period of 1 week. The type of application form was then changed and again had to be applied to one eye only for 7 consecutive days, followed by a final ophthalmic examination. The mean irritation score was recorded at day 7 and at day 21 of the study. Volunteers had no history of eye disease, no acute pathology of the eye, no contact lenses, no conditional foreign body of the cornea within the last four weeks prior to the study or within the study, no local therapy, no systemic therapy, no diabetes, no pregnancy. Informed consent was obtained. At day 1 one of the two application forms was given to each volunteer in a randomized order. 29 volunteers finished the protocol (16 male, 13 female); mean age: 26 years (range 20-32 years). The mean irritation score of NODS: 35 (2-81); the mean irritation score of Isopto-Naturale(R): 80.4(45.5-99). The difference of mean irritation score (NODS vs. Isopto-Naturale(R)): 46.7 (3.3-82.1) (p < 0.01). The results of the study indicate that in healthy volunteers NODS are not as well tolerated as conventional eye drops when compared for ocular discomfort. However, the chance of applying drugs without preservatives and the possibility of increasing the rate of bioavailability from the new route (NODS) as well as the proportionally reduced risk to the patient of systemic side effects after NODS application of any type of drugs should be taken into consideration.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 50 条
  • [41] A BIOERODIBLE DRUG-DELIVERY SYSTEM CONTAINING METRONIDAZOLE
    BIREK, P
    GRAD, H
    GATES, K
    BAEHNI, P
    LEE, PI
    JOURNAL OF DENTAL RESEARCH, 1994, 73 : 306 - 306
  • [42] Ocular tolerability of Eudragit RS100® and RL1009® nanosuspensions as carriers for ophthalmic controlled drug delivery
    Pignatello, R
    Bucolo, C
    Puglisi, G
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (12) : 2636 - 2641
  • [43] RADIOLOGICAL INSERTION OF AN IMPLANTABLE DRUG-DELIVERY SYSTEM
    LOPEZ, AJ
    SIDHU, PS
    DUTKA, D
    COUSINS, C
    BRITISH JOURNAL OF RADIOLOGY, 1994, 67 (797): : 491 - 493
  • [44] NOVEL DRUG-DELIVERY SYSTEM BY CHITIN DERIVATIVE
    TOKURA, S
    NISHI, N
    TAKAHASHI, K
    SHIRAI, A
    URAKI, Y
    MACROMOLECULAR SYMPOSIA, 1995, 99 : 201 - 208
  • [45] New drug-delivery patch for erectile dysfunction
    Nature Biotechnology, 1996, 14 (07):
  • [46] THE TRANSDERMAL DRUG-DELIVERY SYSTEM AND TRANSCUTANEOUS ABSORPTION
    MORIMOTO, Y
    SUGIBAYASHI, K
    NATSUME, H
    ACTA DERMATO-VENEREOLOGICA, 1994, : 15 - 17
  • [47] NEW DEVELOPMENT ON HYDROGELS - POTENTIAL IN DRUG-DELIVERY
    SINGH, R
    AWASTHI, S
    VYAS, SP
    PHARMAZIE, 1993, 48 (10): : 728 - 731
  • [48] Special focus issue: ocular and ophthalmic drug delivery systems
    McConville, Jason
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2016, 42 (04) : 513 - 513
  • [49] Biological macromolecules for ophthalmic drug delivery to treat ocular diseases
    Krishnaswami, Venkateshwaran
    Kandasamy, Ruckmani
    Alagarsamy, Shanmugarathinam
    Palanisamy, Rajaguru
    Natesan, Subramanian
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 110 : 7 - 16
  • [50] Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases
    Tsung, Ta-Hsin
    Tsai, Yu-Chien
    Lee, Hsin-Pei
    Chen, Yi-Hao
    Lu, Da-Wen
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)